Chinese Blood Product Marketplace Analysed in In-demand ResearchInChina Report Available at MarketPublishers.com09 Jun 2015 • by Natalie Aster
LONDON – Amidst the industrial prosperity and favourable policies, the country’s production-use blood plasma volume surpassed the 4, 000-tonne mark and the overall lot release volume grew by 15% YoY to 52.4 million bottles as of 2014. In terms of lot release volume, human albumin, human rabies immunoglobulin (HRIG), human immunoglobulin (ph4) for intravenous injection and tetanus immunoglobulin (TIG) were the leading blood products country-wide in 2014, capturing shares of around 60%, 14.6%, 13.6% and 4.1% of the total lot release volume respectively.
Meantime, R&D capabilities and supply of human blood coagulation factor VIII, human prothrombin complex, and other small products in rigid demand have increased in the recent past. In 2014, the lot release volume of the 2 above mentioned products increased by respectively just under 44% and 46.3% YoY. Chengdu Rongsheng, Yuanda Shuyang, Guangdong Danxia, Shanxi Kangbao and other companies got FDA approval for their human blood coagulation factor VIII as of 2014.
Considering tight requirements on novel local plasma stations, China Biologic Products, Tiantan Biological, Shanghai RAAS, Yuanda Shuyang and Hualan Biological Engineering are the 5 leading companies active in the national blood product industry, accounting for 61.3% of the country’s production-use volume of plasma and just over 33.5% of its blood product revenues as of 2014.
In-demand study “China Blood Product Industry Report, 2015-2018” drawn up by ResearchInChina is devoted to an in-depth analysis of the Chinese blood product industry.
The report gives accurate insights into market characteristics, business environment, current position, among others, of the industry. It provides an analysis of the supply and demand, competitive scenario, export & import dynamics, development forecasts, etc. of China’s blood product industry. The study canvasses the demand and supply, competitive landscape of 8 blood product segments. Information on business operations, blood product development and business prospects of the 12 leading domestic blood product enterprises is available. Furthermore, the study speculates on the future development of the blood product industry in China.
China Blood Product Industry Report, 2015-2018
Published: April, 2015
Price: US$ 2,500.00
More reports by the publisher can be found at ResearchInChina page.